Loading...
01/11 03:08
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals. While the company reports strong year-over-year revenue and EBITDA growth, challenges in the plasma business and operational costs pose risks. The Q&A reveals uncertainty in future revenue from new programs and the Gamma acquisition. The share repurchase program offers some positive sentiment, but concerns about regulatory pressures and economic factors balance the outlook. The lack of clear guidance on new programs and potential plasma business pressures contribute to a neutral sentiment.
Total Revenue $58.4 million, an increase of 23.5% year-over-year.
Adjusted EBITDA $9.6 million, an increase of 43.3% year-over-year.
Adjusted EBITDA Margin 16.5%, an improvement of 230 basis points year-over-year.
Patient Affordability Revenue $12.7 million, a growth of 212% year-over-year from $4.1 million.
Plasma Revenue $43.9 million, a 4.6% increase from $42 million in 2023.
Fourth Quarter Total Revenue $15.6 million, an increase of $1.9 million or 14% year-over-year.
Fourth Quarter Gross Profit Margin 58.9%, up from 52.2% year-over-year.
Fourth Quarter SG&A Expenses $6.3 million, an increase of 36.7% year-over-year.
Fourth Quarter Net Income $1.4 million or $0.02 per diluted share, down from $5.6 million or $0.05 per diluted share year-over-year.
Fourth Quarter Adjusted EBITDA $2.9 million or $0.05 per diluted share, up from $2.5 million or $0.05 per diluted share year-over-year.
Cash Balance $10.8 million, a decrease of $6.3 million year-over-year.
Share Repurchases (Q4 2024) 36,700 shares for approximately $135,000.
Share Repurchases (Full Year 2024) 136,700 shares for approximately $495,000.
New Product Acquisition: Paysign announced the acquisition of Gamma Innovation LLC, enhancing capabilities in plasma donor and pharmaceutical patient engagement.
Software-as-a-Service Market Entry: The acquisition marks Paysign's entry into the high-margin software-as-a-service market, expanding their total addressable market.
Market Expansion in Patient Affordability: The patient affordability business grew 212% year-over-year, reaching $12.7 million in revenue, with expectations to double again in 2025.
Plasma Center Expansion: Exited 2024 with 480 plasma centers, an increase of 16 centers, with plans to add 10 to 15 more in 2025.
Operational Efficiency: Adjusted EBITDA increased 43.3% to $9.6 million, with margins improving by 230 basis points to 16.5%.
Sales Cycle Efficiency: Sales cycle remains efficient within the 90 to 120 day range, with a robust sales pipeline.
Strategic Shift in Business Model: Focus on expanding depth and breadth of solutions to create new revenue streams, integrating payments into consumer engagement.
Plasma Business Challenges: The plasma donor compensation business experienced a revenue decline of 6.2% in Q4 2024, primarily due to fractionators managing an oversupply of source plasma and increased donation yields from hardware upgrades, leading to reduced donor compensation payments.
Regulatory and Market Pressures: The company anticipates continued challenges in the plasma business through at least the remainder of 2025 due to excess inventory and market conditions.
Operational Costs: Operating expenses are projected to be between $47.5 million and $50 million in 2025, reflecting ongoing investments in technology and personnel, which may impact profitability.
Economic Factors: The company expects revenue to be higher in the first half of 2025 compared to the second half, indicating potential seasonality effects that could impact overall financial performance.
Acquisition Risks: The acquisition of Gamma Innovation LLC introduces integration risks and the need to achieve anticipated operating synergies, which may affect financial outcomes.
Patient Affordability Business Growth: Annual revenue in this segment grew 212% year-over-year, reaching $12.7 million compared to $4.1 million in 2023.
Acquisition of Gamma Innovation LLC: This strategic acquisition significantly enhances our capability to offer integrated solutions for plasma donor and pharmaceutical patient engagement.
Expansion of Plasma Centers: We exited 2024 with 480 centers, an increase of 16 centers over the previous year, and anticipate adding an additional 10 to 15 centers in 2025.
2025 Revenue Guidance: Expect total revenues to be in the range of $68.5 million to $70 million, reflecting year-over-year growth of 17.5% to 20%.
2025 Adjusted EBITDA Guidance: Expected to be in the range of $12.5 million and $13.5 million or $0.22 to $0.24 per diluted share.
2025 Gross Profit Margin Guidance: Expected to be between 62% and 64%.
Q1 2025 Revenue Guidance: Expect total revenue to be in the range of $17.5 million to $18 million.
Q1 2025 Adjusted EBITDA Guidance: Expected to be in the range of $4 million and $5 million, or 21.7% to 27.2% of revenue.
Share Repurchase Program: In the fourth quarter, Paysign repurchased 36,700 shares for approximately $135,000. For the full year, a total of 136,700 shares were repurchased for approximately $495,000.
The earnings call indicates strong growth prospects, with significant year-over-year improvements in financial metrics, increased revenue guidance, and operational efficiencies. The Q&A section supports optimism with plans for new programs and systems, despite management's lack of specific details. The raised revenue guidance and anticipated FDA approval for new systems suggest positive momentum. However, the lack of clear guidance on some metrics and confidentiality constraints slightly temper the outlook, preventing a 'Strong positive' rating.
The company's earnings call indicates strong financial performance, with significant revenue growth and improved margins driven by the patient affordability business. Despite some decline in plasma revenue, the overall outlook is optimistic with a promising pipeline of new programs and operational efficiencies. The Q&A section suggests positive sentiment from analysts, with inquiries focused on growth and expansion. The strategic acquisition and efficient operations further enhance prospects, leading to a positive stock price prediction.
The earnings report shows strong financial performance with a 41% revenue increase and a 737% net income rise. The acquisition of Gamma Innovation is expected to add significant cash flow and enhance tech capabilities. Although plasma revenue declined, pharma revenue is growing rapidly. The company's guidance indicates strong growth, and a share repurchase program is in place. However, management's refusal to provide specific future revenue targets and challenges in the plasma segment are concerns. Overall, the positive financial metrics and strategic initiatives outweigh these concerns, suggesting a positive stock price movement.
The earnings call presents mixed signals. While the company reports strong year-over-year revenue and EBITDA growth, challenges in the plasma business and operational costs pose risks. The Q&A reveals uncertainty in future revenue from new programs and the Gamma acquisition. The share repurchase program offers some positive sentiment, but concerns about regulatory pressures and economic factors balance the outlook. The lack of clear guidance on new programs and potential plasma business pressures contribute to a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
